A high number of patient life-years are lost to regulatory delays for drug approvals, according to an analysis presented at the 2015 World Conference on Lung Cancer.
Practice & Policy
Adding pertuzumab to first-line therapy for HER2-positive breast cancer has been shown to yield a survival benefit, but a new analysis says adding the drug is not cost effective.
This slide show looks at patient access to oncology agents both in the United States and abroad, and examines barriers and other constraints preventing new treatments from getting into the hands of patients.
A study found varying degrees of costs and benefits associated with granting early access to drugs based on PFS. In many cases, costs outstripped the benefits.
More and more cancer patients are surviving their diseases as better treatments become available, and while that’s good news, it poses challenges for clinicians.
Ahead of the World Tobacco Congress, Dr. Alan Blum and Cancer Network have partnered to assemble a four-part slideshow series addressing the history of America’s smoking pandemic. Part 1 examines the early evidence linking smoking with cancer.
The US Food and Drug Administration has approved filgrastim-sndz (Zarxio), a biosimilar of filgrastim (Neupogen), and the first such agent to be approved in the United States.
A new study suggests that cancer patients do not often request unnecessary and sometimes costly tests or treatments.
CMS has launched a new multi-payer cancer payment model that reimburses oncologists for episodes of care surrounding chemotherapy treatment, part of a larger effort by the agency to reward physicians based on quality rather than quantity of care.
An FDA advisory panel unanimously endorsed EP2006, a biosimilar of filgrastim, a biologic used to treat neutropenia caused by chemotherapy treatment.